NEXGEL to Report Second Quarter 2025 Financial Results on August 12th
Rhea-AI Summary
NEXGEL (NASDAQ: NXGL), a provider of ultra-gentle hydrogel products for healthcare and consumer applications, will release its Q2 2025 financial results on August 12, 2025, after market close.
The company will host a conference call at 4:30 P.M. ET on the same day. Investors can join via phone at 1-800-274-8461 (U.S.) or 1-203-518-9814 (International). A replay will be available through August 26, 2025, and the webcast will be archived for 90 days.
Positive
- None.
Negative
- None.
Management will host a conference call at 4:30 P.M. ET on the same day
LANGHORNE, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2025, after the market close on August 12, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day.
Second Quarter 2025 Financial Results Conference Call
Date: August 12, 2025
Time: 4:30 P.M. ET
Live Call: 1-800-274-8461 (U.S. Toll Free) or 1-203-518-9814 (International)
Webcast: Events and Presentations
For interested individuals unable to join the conference call, a replay will be available through August 26, 2025, by dialing + 1-844-512-2921 (U.S. Toll Free) or + 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11159686. An archived version of the webcast will also be available for 90 days.
About NEXGEL, INC.
NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies.
Investor Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Nexgel@KCSA.com
FAQ
When will NEXGEL (NXGL) report Q2 2025 earnings?
How can investors access NEXGEL's Q2 2025 earnings call?
What is the replay information for NEXGEL's Q2 2025 earnings call?
What does NEXGEL (NXGL) company do?
